Compare Citius Pharmaceuticals Inc (CTXR) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Oxford Lane Capital Corp trades at $8.53 (market cap $835.71M). The key difference: Oxford Lane Capital Corp is far larger — about 61.4× Citius Pharmaceuticals Inc's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Oxford Lane Capital Corp for 49 Days on average.
| CTXR | OXLC | |
|---|---|---|
Market Cap | $13.62M | $835.71M |
Volume | 132,438 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $1.82 | $16.74 |
52-Week Low | $0.48 | $8.15 |
Typical Hold Time | 16 Days | 49 Days |
Enterprise Value | $3.79M | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook indicated by moving averages and oscillators. Recent earnings misses and a sharp decline in 2026 revenue and net income highlight fundamental challenges, though the stock trades below book value. The company maintains a regular dividend payout, but negative cash flow from operations and high interest expenses pose sustainability concerns.
The outlook is cautious due to deteriorating profitability and bearish sentiment, though deep valuation discounts may attract contrarian investors. Key risks include earnings volatility, dividend coverage, and market sentiment shifts. Analyst consensus is mixed, with half recommending buy but technicals signaling sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
